Question · asked by 1 review
Aciclovir (systemic; 800 mg 5x/day for 1 week then 400 mg 2x/day for 11 weeks) vs placebo: Episode frequency associated with oral ulcers
- Population
- People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
- Intervention
- Aciclovir (systemic; 800 mg 5x/day for 1 week then 400 mg 2x/day for 11 weeks)
- Comparison
- placebo
- Outcome
- Episode frequency associated with oral ulcers
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Aciclovir (systemic; 800 mg 5x/day for 1 week then 400 mg 2x/day for 11 weeks) vs Placebo Frequency of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically;… Interventions for managing oral ulcers in Behçet's disease (2014) · Cochrane All outcomes | Davies 1988 (aciclovir vs placebo, 36 patients, cross-over; high risk of reporting bias; concomitant treatments): data were not presented in a usable format; authors reported no statistically significant difference in… | 1 study · 36 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for managing oral ulcers in Behçet's disease 2014 · Cochrane All outcomes | 2013-10 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.